サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1689656

皮膚線維症治療薬市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)

Cutaneous Fibrosis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 297 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.36円
皮膚線維症治療薬市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)
出版日: 2025年03月25日
発行: Persistence Market Research
ページ情報: 英文 297 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の皮膚線維症治療薬市場に関する包括的なレポートを発表しました。当レポートでは、市場促進要因・動向・機会・促進要因・課題など、重要な市場ダイナミクスを徹底的に評価し、市場構造に関する詳細な洞察を提供しています。この調査レポートは、2025年から2032年までの世界の皮膚線維症治療薬市場の予測成長軌道を概説する独占データと統計を掲載しています。

主要な洞察

  • 皮膚線維症治療薬の市場規模 (2025年)：7億3,200万米ドル
  • 市場規模の予測 (金額ベース、2032年)：11億7,320万米ドル
  • 世界市場の成長率 (CAGR、2025～2032年)：7.0%

皮膚線維症治療薬市場：分析範囲

皮膚線維症は、創傷治癒過程の異常による過剰な瘢痕化と組織の硬化を特徴とする病的状態です。一般に、全身性硬化症、ケロイド、放射線誘発性線維症などの疾患と関連しています。治療アプローチは、副腎皮質ステロイドや抗線維化剤などの薬理学的介入から、レーザー治療、幹細胞治療、再生医療などの先進治療まで多岐にわたる。同市場は、病院、皮膚科クリニック、研究機関、在宅医療を対象としています。市場成長の原動力は、線維性皮膚疾患の有病率の増加、新規治療アプローチの採用の増加、再生医療や生物製剤の進歩です。

市場成長の促進要因：

世界の皮膚線維症治療薬市場は、強皮症、ケロイド、放射線誘発性線維症などの疾患の罹患率の上昇など、いくつかの重要な要因によって推進されています。利用可能な治療オプションに関する認識の高まりと皮膚科学研究への投資の増加が、市場拡大に寄与しています。さらに、新規の生物学的治療、遺伝子ベースの治療、抗線維化薬の導入は、治療効果を高め、患者の転帰を改善しています。幹細胞治療や多血小板血漿（PRP）治療を含む再生医療の役割の拡大は、線維性皮膚疾患に対する革新的な治療選択肢を提供することで、市場の成長をさらに促進しています。

市場の抑制要因：

力強い成長が見込まれるもの、皮膚線維症治療薬市場は、高い治療費、標的治療薬の限定的な入手可能性、新薬承認に伴う規制上のハードルなどの課題に直面しています。線維症の複雑な病態生理が薬剤開発を困難にしており、臨床試験期間の長期化と研究開発費の増大を招いています。さらに、標準化された治療プロトコールがないことや、先進的治療に対する保険適用が限られていることが、特に新興経済国において、市場浸透の課題となっています。これらの障壁に対処するには、研究協力の拡大、償還制度の改善、新規治療法に対する規制当局の支援が必要です。

市場機会：

皮膚線維症治療薬市場は、個別化医療の進展、併用療法の採用拡大、低侵襲治療の選択肢の拡大により、大きな成長機会がもたらされます。線維症治療におけるAI主導の診断ツールと予測モデリングの統合により、早期診断と治療効果の向上が期待されます。さらに、抗線維化薬の創薬研究の拡大と、皮膚への浸透性を高めた局所療法の開発は、有利な市場展望をもたらします。製薬企業と研究機関の戦略的パートナーシップは、技術革新を加速し、治療へのアクセスを拡大する上で重要な役割を果たすと思われます。

当レポートで回答する主な質問

  • 皮膚線維症治療薬市場の世界的成長を促進する主な要因は何か？
  • 皮膚線維症の治療で最も採用されている治療方法と薬剤クラスはどれか？
  • 技術進歩は市場の競合情勢をどのように形成しているか？
  • 市場に貢献している主要企業はどれか？市場の関連性を維持するためにどのような戦略を採用しているのか？
  • 世界の皮膚線維症治療薬市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 主な動向
  • マクロ経済要因
    • 世界の部門別の展望
    • 世界のGDP成長の見通し
  • COVID-19の影響分析
  • 予測要因：関連性と影響

第3章 付加価値の洞察

  • 製品採用分析
  • 規制状況
  • バリューチェーン分析
  • PESTLE分析
  • ポーターのファイブフォース分析

第4章 世界の皮膚線維症治療薬市場の展望

  • 主なハイライト
    • 市場規模と前年比成長率 (10億米ドル)
    • 絶対的収益機会
  • 市場規模の分析と予測 (10億米ドル)
    • 過去の市場規模の分析 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測 (10億米ドル、2025～2032年)
  • 世界の皮膚線維症治療薬市場の展望：薬剤クラス別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：薬剤クラス別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：薬剤クラス別 (10億米ドル、2025～2032年)
      • コルチコステロイド
      • 抗線維化薬
      • 免疫療法
        • 免疫グロブリン
        • 免疫抑制剤
        • ヤヌスキナーゼ（JAK）阻害剤
        • その他
    • 市場魅力分析：薬剤クラス別
  • 世界の皮膚線維症治療薬市場の展望：投与経路別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：投与経路別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：投与経路別 (10億米ドル、2025～2032年)
      • 経口薬
      • 注射薬
      • 外用薬
    • 市場魅力分析：投与経路別
  • 世界の皮膚線維症治療薬市場の展望：適応症別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：適応症別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：適応症別 (10億米ドル、2025～2032年)
      • ケロイド
      • 強皮症
      • 放射線誘発性皮膚線維症
      • 慢性移植片対宿主病（GvHD）関連皮膚線維症
      • その他
    • 市場魅力分析：適応症別
  • 世界の皮膚線維症治療薬市場の展望：流通チャネル別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：流通チャネル別 (10億米ドル、2019～2024年)
    • 現在の市場規模の分析と予測：流通チャネル別 (10億米ドル、2025～2032年)
      • 病院薬局
      • 小売薬局
      • オンライン薬局
    • 市場魅力分析：流通チャネル別

第5章 世界の皮膚線維症治療薬市場の展望：地域別

  • 主なハイライト
  • 過去の市場規模の分析：地域別 (10億米ドル、2019～2024年)
  • 現在の市場規模の分析と予測：地域別 (10億米ドル、2025～2032年)
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第6章 北米の皮膚線維症治療薬市場の展望

第7章 欧州の皮膚線維症治療薬市場の展望

第8章 東アジアの皮膚線維症治療薬市場の展望

第9章 南アジアおよびオセアニアの皮膚線維症治療薬市場の展望

第10章 ラテンアメリカの皮膚線維症治療薬市場の展望

第11章 中東およびアフリカの皮膚線維症治療薬市場の展望

第12章 競合情勢

  • 市場シェア分析 (2025年)
  • 市場構造
    • 競合強度マップ：市場別
    • 競合ダッシュボード
  • 企業プロファイル (詳細：概要、財務、戦略、最近の動向)
    • Novartis AG
    • Pfizer
    • Sanofi
    • F. Hoffmann-La Roche（Genentech, Inc.）
    • Boehringer Ingelheim International GmbH
    • Jubilant Cadista
    • Horizon Therapeutics USA, Inc.
    • Bristol-Myers Squibb Company
    • Teva Pharmaceuticals
    • Amgen
    • Johnson &Johnson Services
    • AbbVie
    • Bayer
    • Merck &Co.
    • GlaxoSmithKline
    • LEO Pharma
    • Actelion Pharmaceuticals

第13章 付録

  • 分析手法
  • 分析の前提条件
  • 頭字語と略語
目次
Product Code: PMRREP33114

Persistence Market Research has recently released a comprehensive report on the global cutaneous fibrosis treatment market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global cutaneous fibrosis treatment market from 2025 to 2032.

Key Insights:

  • Cutaneous Fibrosis Treatment Market Size (2025E): USD 732.0 Million
  • Projected Market Value (2032F): USD 1,173.2 Million
  • Global Market Growth Rate (CAGR 2025 to 2032): 7.0%

Cutaneous Fibrosis Treatment Market -

Report Scope:

Cutaneous fibrosis is a pathological condition characterized by excessive scarring and tissue hardening due to abnormal wound healing processes. It is commonly associated with conditions such as systemic sclerosis, keloids, and radiation-induced fibrosis. Treatment approaches range from pharmacological interventions, including corticosteroids and antifibrotic agents, to advanced therapies such as laser treatment, stem cell therapy, and regenerative medicine. The market caters to hospitals, dermatology clinics, research institutions, and homecare settings. Market growth is driven by increasing prevalence of fibrotic skin disorders, rising adoption of novel therapeutic approaches, and advancements in regenerative medicine and biologics.

Market Growth Drivers:

The global cutaneous fibrosis treatment market is propelled by several key factors, including rising incidence of conditions such as scleroderma, keloids, and radiation-induced fibrosis. Increasing awareness regarding available treatment options, coupled with growing investments in dermatological research, is contributing to market expansion. Additionally, the introduction of novel biologic therapies, gene-based treatments, and anti-fibrotic drugs is enhancing treatment efficacy and improving patient outcomes. The expanding role of regenerative medicine, including stem cell therapies and platelet-rich plasma (PRP) treatments, is further driving market growth by offering innovative treatment options for fibrotic skin disorders.

Market Restraints:

Despite strong growth prospects, the cutaneous fibrosis treatment market faces challenges, including high treatment costs, limited availability of targeted therapies, and regulatory hurdles associated with the approval of new drugs. The complex pathophysiology of fibrosis makes drug development challenging, leading to extended clinical trial durations and increased R&D expenditures. Additionally, the lack of standardized treatment protocols and limited insurance coverage for advanced therapies pose challenges for market penetration, particularly in emerging economies. Addressing these barriers requires increased research collaboration, improved reimbursement frameworks, and regulatory support for novel treatment modalities.

Market Opportunities:

The cutaneous fibrosis treatment market presents significant growth opportunities driven by advancements in personalized medicine, increasing adoption of combination therapies, and expansion of minimally invasive treatment options. The integration of AI-driven diagnostic tools and predictive modeling in fibrosis treatment is expected to enhance early diagnosis and treatment effectiveness. Furthermore, growing research in anti-fibrotic drug discovery and the development of topical therapies with improved skin penetration offer lucrative market prospects. Strategic partnerships between pharmaceutical companies and research institutes will play a vital role in accelerating innovation and expanding treatment accessibility.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the cutaneous fibrosis treatment market globally?
  • Which treatment modalities and drug classes are witnessing the highest adoption in cutaneous fibrosis management?
  • How are technological advancements shaping the competitive landscape of the market?
  • Who are the key players contributing to the market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global cutaneous fibrosis treatment market?

Competitive Intelligence and Business Strategy:

Leading players in the global cutaneous fibrosis treatment market, including Pfizer Inc., Sanofi S.A., and F. Hoffmann-La Roche Ltd., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. Companies are investing in R&D to develop novel antifibrotic drugs, biologics, and stem cell-based therapies. Collaborations with academic institutions and biotechnology firms are accelerating drug discovery and clinical trials for emerging treatment options. Additionally, companies are expanding their global presence through strategic mergers, acquisitions, and partnerships to strengthen their product portfolios and enhance market penetration.

Key Companies Profiled:

  • Novartis AG
  • Pfizer
  • Sanofi
  • F. Hoffmann-La Roche (Genentech, Inc.)
  • Boehringer Ingelheim International GmbH
  • Jubilant Cadista
  • Horizon Therapeutics USA, Inc.
  • Bristol-Myers Squibb Company
  • Teva Pharmaceuticals
  • Amgen
  • Johnson & Johnson Services
  • AbbVie
  • Bayer
  • Merck & Co.
  • GlaxoSmithKline
  • LEO Pharma
  • Actelion Pharmaceuticals

Key Segments Covered in Cutaneous Fibrosis Treatment Industry Research

Cutaneous Fibrosis Treatment Market by Drug Class:

  • Corticosteroids
  • Anti-fibrotic Drugs
  • Immunotherapy
  • Immunoglobulins

Cutaneous Fibrosis Treatment Market by Route of Administration:

  • Oral
  • Injectable
  • Topical

Cutaneous Fibrosis Treatment Market by Indication:

  • Keloid
  • Scleroderma
  • Radiation-induced Skin Fibrosis
  • Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis

Cutaneous Fibrosis Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia & Oceania
  • East Asia
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Cutaneous Fibrosis Treatment Market Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Value Chain Analysis
  • 3.4. PESTLE Analysis
  • 3.5. Porter's Five Force Analysis

4. Global Cutaneous Fibrosis Treatment Market Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Cutaneous Fibrosis Treatment Market Outlook: Drug Class
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
      • 4.3.3.1. Corticosteroids
      • 4.3.3.2. Anti-fibrotic Drugs
      • 4.3.3.3. Immunotherapy
        • 4.3.3.3.1. Immunoglobulins
        • 4.3.3.3.2. Immunosuppressants
        • 4.3.3.3.3. Janus Kinase (JAK) Inhibitors
        • 4.3.3.3.4. Others
    • 4.3.4. Market Attractiveness Analysis: Drug Class
  • 4.4. Global Cutaneous Fibrosis Treatment Market Outlook: Route of Administration
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Route of Administration, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
      • 4.4.3.1. Oral
      • 4.4.3.2. Injectable
      • 4.4.3.3. Topical
    • 4.4.4. Market Attractiveness Analysis: Route of Administration
  • 4.5. Global Cutaneous Fibrosis Treatment Market Outlook: Indication
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.5.3.1. Keloid
      • 4.5.3.2. Scleroderma
      • 4.5.3.3. Radiation-induced Skin Fibrosis
      • 4.5.3.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Indication
  • 4.6. Global Cutaneous Fibrosis Treatment Market Outlook: Distribution Channel
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
      • 4.6.3.1. Hospital Pharmacies
      • 4.6.3.2. Retail Pharmacies
      • 4.6.3.3. Online Pharmacies
    • 4.6.4. Market Attractiveness Analysis: Distribution Channel

5. Global Cutaneous Fibrosis Treatment Market Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia & Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Cutaneous Fibrosis Treatment Market Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Drug Class
    • 6.2.3. By Route of Administration
    • 6.2.4. By Indication
    • 6.2.5. By Distribution Channel
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 6.4.1. Corticosteroids
    • 6.4.2. Anti-fibrotic Drugs
    • 6.4.3. Immunotherapy
      • 6.4.3.1. Immunoglobulins
      • 6.4.3.2. Immunosuppressants
      • 6.4.3.3. Janus Kinase (JAK) Inhibitors
      • 6.4.3.4. Others
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 6.5.1.
      • 6.5.1.1. Oral
      • 6.5.1.2. Injectable
      • 6.5.1.3. Topical
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.6.1.
      • 6.6.1.1. Keloid
      • 6.6.1.2. Scleroderma
      • 6.6.1.3. Radiation-induced Skin Fibrosis
      • 6.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
      • 6.6.1.5. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 6.7.1.
      • 6.7.1.1. Hospital Pharmacies
      • 6.7.1.2. Retail Pharmacies
      • 6.7.1.3. Online Pharmacies
  • 6.8. Market Attractiveness Analysis

7. Europe Cutaneous Fibrosis Treatment Market Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Drug Class
    • 7.2.3. By Route of Administration
    • 7.2.4. By Indication
    • 7.2.5. By Distribution Channel
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 7.4.1. Corticosteroids
    • 7.4.2. Anti-fibrotic Drugs
    • 7.4.3. Immunotherapy
      • 7.4.3.1. Immunoglobulins
      • 7.4.3.2. Immunosuppressants
      • 7.4.3.3. Janus Kinase (JAK) Inhibitors
      • 7.4.3.4. Others
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 7.5.1.
      • 7.5.1.1. Oral
      • 7.5.1.2. Injectable
      • 7.5.1.3. Topical
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.6.1.
      • 7.6.1.1. Keloid
      • 7.6.1.2. Scleroderma
      • 7.6.1.3. Radiation-induced Skin Fibrosis
      • 7.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
      • 7.6.1.5. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 7.7.1.
      • 7.7.1.1. Hospital Pharmacies
      • 7.7.1.2. Retail Pharmacies
      • 7.7.1.3. Online Pharmacies
  • 7.8. Market Attractiveness Analysis

8. East Asia Cutaneous Fibrosis Treatment Market Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By Indication
    • 8.2.5. By Distribution Channel
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 8.4.1. Corticosteroids
    • 8.4.2. Anti-fibrotic Drugs
    • 8.4.3. Immunotherapy
      • 8.4.3.1. Immunoglobulins
      • 8.4.3.2. Immunosuppressants
      • 8.4.3.3. Janus Kinase (JAK) Inhibitors
      • 8.4.3.4. Others
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 8.5.1.
      • 8.5.1.1. Oral
      • 8.5.1.2. Injectable
      • 8.5.1.3. Topical
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.6.1.
      • 8.6.1.1. Keloid
      • 8.6.1.2. Scleroderma
      • 8.6.1.3. Radiation-induced Skin Fibrosis
      • 8.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
      • 8.6.1.5. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 8.7.1.
      • 8.7.1.1. Hospital Pharmacies
      • 8.7.1.2. Retail Pharmacies
      • 8.7.1.3. Online Pharmacies
  • 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Cutaneous Fibrosis Treatment Market Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By Indication
    • 9.2.5. By Distribution Channel
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 9.4.1. Corticosteroids
    • 9.4.2. Anti-fibrotic Drugs
    • 9.4.3. Immunotherapy
      • 9.4.3.1. Immunoglobulins
      • 9.4.3.2. Immunosuppressants
      • 9.4.3.3. Janus Kinase (JAK) Inhibitors
      • 9.4.3.4. Others
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 9.5.1.
      • 9.5.1.1. Oral
      • 9.5.1.2. Injectable
      • 9.5.1.3. Topical
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.6.1.
      • 9.6.1.1. Keloid
      • 9.6.1.2. Scleroderma
      • 9.6.1.3. Radiation-induced Skin Fibrosis
      • 9.6.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
      • 9.6.1.5. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 9.7.1.
      • 9.7.1.1. Hospital Pharmacies
      • 9.7.1.2. Retail Pharmacies
      • 9.7.1.3. Online Pharmacies
  • 9.8. Market Attractiveness Analysis

10. Latin America Cutaneous Fibrosis Treatment Market Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By Indication
    • 10.2.5. By Distribution Channel
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 10.4.1. Corticosteroids
    • 10.4.2. Anti-fibrotic Drugs
    • 10.4.3. Immunotherapy
      • 10.4.3.1. Immunoglobulins
      • 10.4.3.2. Immunosuppressants
      • 10.4.3.3. Janus Kinase (JAK) Inhibitors
      • 10.4.3.4. Others
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 10.5.1. Oral
    • 10.5.2. Injectable
    • 10.5.3. Topical
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.6.1. Keloid
    • 10.6.2. Scleroderma
    • 10.6.3. Radiation-induced Skin Fibrosis
    • 10.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 10.7.1.
      • 10.7.1.1. Hospital Pharmacies
      • 10.7.1.2. Retail Pharmacies
      • 10.7.1.3. Online Pharmacies
  • 10.8. Market Attractiveness Analysis

11. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Drug Class
    • 11.2.3. By Route of Administration
    • 11.2.4. By Indication
    • 11.2.5. By Distribution Channel
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2025-2032
    • 11.4.1. Corticosteroids
    • 11.4.2. Anti-fibrotic Drugs
    • 11.4.3. Immunotherapy
      • 11.4.3.1. Immunoglobulins
      • 11.4.3.2. Immunosuppressants
      • 11.4.3.3. Janus Kinase (JAK) Inhibitors
      • 11.4.3.4. Others
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Route of Administration, 2025-2032
    • 11.5.1. Oral
    • 11.5.2. Injectable
    • 11.5.3. Topical
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.6.1. Keloid
    • 11.6.2. Scleroderma
    • 11.6.3. Radiation-induced Skin Fibrosis
    • 11.6.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2025-2032
    • 11.7.1. Hospital Pharmacies
    • 11.7.2. Retail Pharmacies
    • 11.7.3. Online Pharmacies

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Novartis AG
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Pfizer
    • 12.3.3. Sanofi
    • 12.3.4. F. Hoffmann-La Roche (Genentech, Inc.)
    • 12.3.5. Boehringer Ingelheim International GmbH
    • 12.3.6. Jubilant Cadista
    • 12.3.7. Horizon Therapeutics USA, Inc.
    • 12.3.8. Bristol-Myers Squibb Company
    • 12.3.9. Teva Pharmaceuticals
    • 12.3.10. Amgen
    • 12.3.11. Johnson & Johnson Services
    • 12.3.12. AbbVie
    • 12.3.13. Bayer
    • 12.3.14. Merck & Co.
    • 12.3.15. GlaxoSmithKline
    • 12.3.16. LEO Pharma
    • 12.3.17. Actelion Pharmaceuticals

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations